Sunovion Pharmaceuticals Inc. Presents Positive Results From Two Phase 3 Studies Of Once-Daily Aptiom® (Eslicarbazepine Acetate) As Monotherapy Treatment For Partial-Onset Seizures

Published: Dec 09, 2013

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

MARLBOROUGH, Mass.--(BUSINESS WIRE)--Sunovion Pharmaceuticals Inc. (Sunovion) today announced results from two Phase 3 trials (Studies 093-046 and 093-045) of Aptiom® (eslicarbazepine acetate) as a monotherapy treatment in patients with partial-onset seizures. Study results showed that APTIOM demonstrated seizure control rates superior to historical controls in patients with partial-onset seizures who were not well-controlled by current antiepileptic drugs (AEDs). These data were presented at the 67th Annual Meeting of the American Epilepsy Society (AES) taking place December 6-10 in Washington, D.C.

Help employers find you! Check out all the jobs and post your resume.

Back to news